Raffles Medical Group Ltd
SGX:BSL
Intrinsic Value
Raffles Medical Group Ltd. is an investment holding company, which engages in the operation of medical clinics and other general medical services. [ Read More ]
The intrinsic value of one
BSL
stock under the Base Case scenario is
0.97
SGD.
Compared to the current market price of 1.03 SGD,
Raffles Medical Group Ltd
is
Overvalued by 6%.
Raffles Medical Group Ltd's market capitalization is 1.9B SGD.
BSL stock price is 1.03 SGD.
BSL stock (0.97 SGD) is 6% less than its price (1.03 SGD).
BSL has upside potential of 14% compared to the average analyst price target.
Open Wall St Estimates
BSL's ROE (Return on Equity) for the past 12 months is positive and is equal to 9%.
BSL's ROIC (Return on Invested Capital) has increased in the last 3 years from 7% to 8%.
BSL's ROE (Return on Equity) has increased in the last 3 years from 8% to 9%.
BSL has positive three-year average ROE (Return on Equity): 11%. The company is efficient at transforming stockholders' equity into net income.
BSL has positive three-year average ROIC (Return on Invested Capital): 11%. The company is efficient at using invested capital to generate operating income.
BSL's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 8%.
BSL's Revenue is forecast to grow at a rate of 3% per year over the next 3 years.
BSL has positive Net Income for the last twelve months.
BSL's Revenue has been growing by 8% per year for the last 3 years.
BSL's short-term assets (485m SGD) exceed its short-term liabilties (379m SGD).
BSL has positive Operating Income for the last twelve months.
BSL's Revenue has dropped by 14% over the past 12 months.
BSL has negative Net Debt. This means that the company has more cash and short-term investments (344m SGD) than debt (174m SGD).
BSL has positive Free Cash Flow for the last twelve months.
BSL has positive Gross Profit for the last twelve months.
BSL's Altman Z-Score is very high and is equal to 3.56.
BSL's long-term assets (2B SGD) exceed its long-term liabilties (500m SGD).
BSL's D/E (Debt to Equity) is very low and is equal to 0.17.
BSL earns more than enough operating income (108m SGD) to safely cover interest payments on its debt (5m SGD).
Valuation Backtest
Raffles Medical Group Ltd
Run backtest to discover the historical profit from buying and selling
BSL
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Raffles Medical Group Ltd
Balance Sheet Decomposition
Raffles Medical Group Ltd
| Current Assets | 484.7m |
| Cash & Short-Term Investments | 343.6m |
| Receivables | 128.6m |
| Other Current Assets | 12.5m |
| Non-Current Assets | 1B |
| Long-Term Investments | 246.1m |
| PP&E | 768.3m |
| Intangibles | 18.8m |
| Other Non-Current Assets | 10.3m |
| Current Liabilities | 379.4m |
| Accounts Payable | 210.7m |
| Short-Term Debt | 91.4m |
| Other Current Liabilities | 77.3m |
| Non-Current Liabilities | 121.1m |
| Long-Term Debt | 82.4m |
| Other Non-Current Liabilities | 38.8m |
Earnings Waterfall
Raffles Medical Group Ltd
|
Revenue
|
706.9m
SGD
|
|
Cost of Revenue
|
-90.6m
SGD
|
|
Gross Profit
|
616.3m
SGD
|
|
Operating Expenses
|
-508.1m
SGD
|
|
Operating Income
|
108.2m
SGD
|
|
Other Expenses
|
-18m
SGD
|
|
Net Income
|
90.2m
SGD
|
Free Cash Flow Analysis
Raffles Medical Group Ltd
BSL Profitability Score
Profitability Due Diligence
Raffles Medical Group Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Raffles Medical Group Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
BSL Solvency Score
Solvency Due Diligence
Raffles Medical Group Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Raffles Medical Group Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BSL Price Targets Summary
Raffles Medical Group Ltd
According to Wall Street analysts, the average 1-year price target for
BSL
is 1.17 SGD
with a low forecast of 0.97 SGD and a high forecast of 1.47 SGD.
Shareholder Return
BSL Price
Raffles Medical Group Ltd
| Average Annual Return | 11.16% |
| Standard Deviation of Annual Returns | 19.65% |
| Max Drawdown | -33% |
| Market Capitalization | 1.9B SGD |
| Shares Outstanding | 1 867 563 900 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Raffles Medical Group Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Raffles Medical Group Ltd. is an investment holding company, which engages in the operation of medical clinics and other general medical services. The firm is focused on providing a range of services from primary and tertiary care to health insurance for people across Asia. The firm operates approximately 100 multi-disciplinary clinics in 14 cities in Singapore, China, Japan, Vietnam and Cambodia. The firm's integrated healthcare organization consists of a tertiary hospital, a network of family medicine and dental clinics, insurance services, Japanese and Traditional Chinese medicine clinics, and a consumer healthcare division. Its healthcare division develops and distributes a range of nutraceuticals, supplements, vitamins and medical diagnostic equipment for personal healthcare in Singapore and in the regional markets. The Company’s subsidiaries include Raffles Medical, Raffles Hospital, Raffles Dental, Raffles Chinese Medicine, Raffles Health Insurance, Raffles Healthcare Institute and Raffles Health.
Contact
IPO
Employees
Officers
The intrinsic value of one
BSL
stock under the Base Case scenario is
0.97
SGD.
Compared to the current market price of 1.03 SGD,
Raffles Medical Group Ltd
is
Overvalued by 6%.
You don't have any saved screeners yet
